$2.20
0[0.00%]
Last update: 9:23AM Get Real Time Here
Oramed Pharmaceuticals
(NASDAQ:ORMP)Oramed Pharmaceuticals Stock (NASDAQ:ORMP), Analyst Ratings, Price Targets, Predictions
Oramed Pharmaceuticals Inc has a consensus price target of $16.4, established from looking at the 11 latest analyst ratings. The last 3 analyst ratings were released from Canaccord Genuity, HC Wainwright & Co., and Canaccord Genuity on May 17, 2023, January 17, 2023, and January 12, 2023. With an average price target of $0.67 between Canaccord Genuity, HC Wainwright & Co., and Canaccord Genuity, there's an implied -69.70% downside for Oramed Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
HC Wainwright & Co.
Aegis Capital
Cantor Fitzgerald
Canaccord Genuity
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Oramed Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 05/17/2023 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.20 | -9.09% | Canaccord Genuity | Edward Nash | $3 → $2 | Maintains | Hold | Get Alert |
| 01/17/2023 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.20 | — | HC Wainwright & Co. | Raghuram Selvaraju | — | Downgrade | Buy → Neutral | Get Alert |
| 01/12/2023 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.20 | — | Canaccord Genuity | Edward Nash | — | Downgrade | Buy → Hold | Get Alert |
| 05/16/2022 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.20 | 1263.64% | Aegis Capital | Nathan Weinstein | $35 → $30 | Maintains | Buy | Get Alert |
| 02/18/2022 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.20 | 809.09% | Cantor Fitzgerald | Charles Duncan | → $20 | Initiates | → Overweight | Get Alert |
| 11/30/2021 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.20 | 1354.55% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
| 11/29/2021 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.20 | 1354.55% | HC Wainwright & Co. | Raghuram Selvaraju | — | Maintains | Buy | Get Alert |
| 11/02/2021 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.20 | 1490.91% | Aegis Capital | Nathan Weinstein | — | Maintains | Buy | Get Alert |
| 07/29/2021 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.20 | 1263.64% | Canaccord Genuity | — | — | Maintains | Buy | Get Alert |
| 06/08/2021 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.20 | 809.09% | Aegis Capital | Nathan Weinstein | — | Maintains | Buy | Get Alert |
| 04/20/2021 | ORMP | Buy Now | Oramed Pharmaceuticals | $2.20 | 1127.27% | Canaccord Genuity | Edward Nash | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Oramed Pharmaceuticals (ORMP)?
The latest price target for Oramed Pharmaceuticals (NASDAQ: ORMP) was reported by Canaccord Genuity on May 17, 2023. The analyst firm set a price target for $2.00 expecting ORMP to fall to within 12 months (a possible -9.09% downside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Oramed Pharmaceuticals (ORMP)?
The latest analyst rating for Oramed Pharmaceuticals (NASDAQ: ORMP) was provided by Canaccord Genuity, and Oramed Pharmaceuticals maintained their hold rating.
When was the last upgrade for Oramed Pharmaceuticals (ORMP)?
There is no last upgrade for Oramed Pharmaceuticals.
When was the last downgrade for Oramed Pharmaceuticals (ORMP)?
The last downgrade for Oramed Pharmaceuticals Inc happened on January 17, 2023 when HC Wainwright & Co. changed their price target from N/A to N/A for Oramed Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Oramed Pharmaceuticals (ORMP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oramed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oramed Pharmaceuticals was filed on May 17, 2023 so you should expect the next rating to be made available sometime around May 17, 2024.
Is the Analyst Rating Oramed Pharmaceuticals (ORMP) correct?
While ratings are subjective and will change, the latest Oramed Pharmaceuticals (ORMP) rating was a maintained with a price target of $3.00 to $2.00. The current price Oramed Pharmaceuticals (ORMP) is trading at is $2.20, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.